The Immune Tolerance Network is currently requesting proposals for the supplementary mechanistic analyses for the remaining participant samples from the Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial.
The GRASS trial is a single-center, randomized, double-blind, double-dummy, placebo-controlled, three-arm study comparing SLIT, SCIT and placebo (randomized 1:1:1) of 106 participants over 3 years’ duration. Participants received 2 years of immunotherapy or placebo followed by a 1-year observation period. Both SCIT and SLIT, when compared to placebo, were successful in inducing desensitization at year 2. There was a broad range of sustained unresponsiveness (year 3) although not significantly different for either treatment group compared to placebo.
Banked serum, PBMC, and nasal fluid from over 80 participants are available for supplementary mechanistic analyses. Most of these participants have all sample types available at all study time points allowing for both longitudinal and cross-sectional analyses.
Deadline: Responses to this RFP will be evaluated upon receipt and the RFP will remain open until the samples have been allocated.